Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-Current Debt (2020 - 2024)

Syndax Pharmaceuticals (SNDX) has disclosed Non-Current Debt for 4 consecutive years, with $331.6 million as the latest value for Q4 2024.

  • For Q4 2024, Non-Current Debt changed N/A year-over-year to $331.6 million; the TTM value through Dec 2024 reached $331.6 million, changed N/A, while the annual FY2024 figure was $331.6 million, N/A changed from the prior year.
  • Non-Current Debt hit $331.6 million in Q4 2024 for Syndax Pharmaceuticals, up from $13.0 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $331.6 million in Q4 2024 and bottomed at $11.0 million in Q3 2021.
  • Average Non-Current Debt over 4 years is $45.3 million, with a median of $17.8 million recorded in 2020.
  • On a YoY basis, Non-Current Debt climbed as much as 11.56% in 2021 and fell as far as 45.07% in 2021.
  • Syndax Pharmaceuticals' Non-Current Debt stood at $17.8 million in 2020, then grew by 11.56% to $19.9 million in 2021, then crashed by 34.69% to $13.0 million in 2022, then surged by 2451.68% to $331.6 million in 2024.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $331.6 million, $13.0 million, and $16.5 million for Q4 2024, Q2 2022, and Q1 2022 respectively.